Cite
HARVARD Citation
Zhong, W. et al. (n.d.). LBA48_PRCTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A randomised study. Annals of oncology. p. . [Online].